North America Multiplex Assays Market

North America Multiplex Assays Market Size (2023 to 2028)

The size of the Multiplex Assays Market in North America is estimated to worth USD 1.22 billion in 2023. This figure is anticipated to reach USD 1.68 billion by 2028  the market is expected to grow at a 6.57% CAGR from 2023 to 2028.

Factors such as the benefits associated with the multiplex assays over the conventional singleplex assays are expected to offer substantial growth in North America. The growing number of immunoassays tests performed and Y-O-Y growth in the incidence rate of chronic and infectious diseases are estimated to propel the market growth during the forecast period. Increasing healthcare expenditure and adopting advanced technologies in the healthcare infrastructure in this region further accelerate market growth.

Refractive errors and the shortage of skilled and experienced professionals hinder the multiplex assays market growth in this region.

This research report on the North America Multiplex Assays Market has been segmented and sub-segmented into the following categories:

• By Product: Consumable, Kits & Reagents and Panels
• By Type: nucleic Acid-Based and Protein-Based
• By Technology: PCR and Multiplex Array
• By Application: R&D and Companion Diagnostics
• By End User: Hospital and Clinical Laboratory
• By Country: The United States, Canada, and Rest of North America

North-America accounts for the largest share of the market. The key factors that drive this market's growth include an increase in the pool of patient population, a rise in the prevalence of Alzheimer patients, and a significant rise in pharmaceuticals research & development activities to treat diseases like cancer and Alzheimer’s.

The U.S. is estimated to rule the North America multiplex assay market due to the government's initiatives in enhancing precision medicine in advance with strategic partners among the critical players in contesting for multiplex assay development. Rising old people population which foster the market.

The Canadian market is predicted to have maximum growth over the historical period. Frequency of cancer cases, investments made by the government for the R&D towards the drug discovery, and the treatment, necessity for the multiplex assay will augment the region as it is a useful oncology tool that fuels the market growth during the assessment period.

Companies playing a dominant role in the North America Multiplex Assays Market profiled in this report are Luminex Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Abcam Plc, Becton, Dickinson and Company, Luminex Corporation, Meso Scale Diagnostics, Randox Laboratories Ltd and Seegene Inc.